Taken together, these findings reveal a novel role of the miR-145-5p/SMAD5/cyclin D1 axis in modulating cell cycle progression and cell proliferation in GC, which may provide a prognostic biomarker for GC treatment. This evidence concerns the gene SMAD5 and gastric cancer.